30165
替罗非班
≥98.5% (HPLC)
别名:
N-（丁基磺酰基）-O-[4-（4-哌啶基）丁基]-L-酪氨酸, （2S）-2-（丁基磺酰基氨基）-3-{4-[4-（4-哌啶基）丁氧基}苯基丙酸
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H36N2O5S
化学文摘社编号:
分子量:
440.60
Beilstein:
6182267
MDL编号:
UNSPSC代码:
12352106
PubChem化学物质编号:
NACRES:
NA.25
质量水平
方案
≥98.5% (HPLC)
表单
powder
SMILES字符串
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O
InChI
1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
InChI key
COKMIXFXJJXBQG-NRFANRHFSA-N
基因信息
human ... ITGA2B(3674), ITGB3(3690)
应用
- The efficacy and safety of continuous intravenous tirofiban for acute ischemic stroke patients treated by endovascular therapy: a meta-analysis.：通过meta分析评估急性缺血性卒中患者血管内治疗中连续静脉给药替罗非班的疗效和安全性，具有改善疗效的满意结果(Wang et al., 2024)。
- Initial Experience with a New Self-Expanding Open-Cell Stent System with Antithrombotic Hydrophilic Polymer Coating (pEGASUS Stent) in the Treatment of Wide-Necked Intracranial Aneurysms.：研究报道首次用新的涂层支架系统治疗颅内动脉瘤（有用到替罗非班），结果疗效和安全性增强(Boxberg et al., 2024)。
包装
无底玻璃瓶。内含物装在插入的融合锥内。
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Jan H Cornel et al.
The American journal of cardiology, 115(10), 1325-1332 (2015-03-18)
We evaluated the interaction between protease-activated receptor-1 antagonist vorapaxar and concomitant glycoprotein (GP) IIb/IIIa receptor inhibitors in patients with non-ST-segment elevation acute coronary syndromes who underwent PCI. In Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Veysel Ozan Tanık et al.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 28(2), 115-123 (2018-11-19)
In this study, we aimed to determine the predictive value of the CHA2DS2VASc score for acute stent thrombosis in patients with an ST elevation myocardial infarction treated with a primary percutaneous coronary intervention (pPCI). This was a retrospective study conducted
Volker Maus et al.
World neurosurgery, 111, e424-e433 (2017-12-27)
Acute dissecting aneurysms of the posterior circulation are a rare cause of subarachnoid hemorrhage. Established endovascular treatment options include parent artery occlusion and stent-assisted coiling, but appear to be associated with an increased risk of ischemic stroke. Vessel reconstruction with
K J McClellan et al.
Drugs, 56(6), 1067-1080 (1999-01-08)
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. Adenosine diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels within 4 to 8 hours
Marco Valgimigli et al.
JACC. Cardiovascular interventions, 5(3), 268-277 (2012-03-24)
The authors sought to compare the effect on inhibition of platelet aggregation (IPA) of prasugrel therapy versus tirofiban bolus with or without a post-bolus short drug infusion in ST-segment elevation myocardial infarction (STEMI) patients. The degree and rapidity of IPA
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持